DHD: Small-cap pharma with limited upside and liquidity constraints
Intrinsic value VND 26,866 vs market VND 26,500 — implied upside +1.4% (model confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược Vật Tư Y Tế Hải Dương (DHD) is a UPCom-listed pharmaceutical distributor/manufacturer operating in the Vietnamese pharmaceuticals segment (ICB: Dược phẩm). The company generated revenue of VND 683.7 bn in 2025 and reported net profit of VND 55.7 bn in 2025, serving local markets and relying on a combination of trading and product distribution activities. Total assets expanded to VND 952.6 bn in 2025, reflecting balance-sheet growth over 2023-25.
Luận điểm đầu tư
The valuation implies virtually no margin of safety: intrinsic value per share is VND 26,866 versus a market price of VND 26,500, for an upside of only 1.4% and model confidence flagged as very_low. At current multiples the stock trades at P/E 17.1x and P/B 1.9x with ROE of 11.6% and ROA of 7.0%, indicating moderate profitability but not a clear discount relative to risk. Recent top-line momentum is muted (revenue CAGR ~3.6% historical blend; 2025 revenue VND 683.7 bn) while net profit grew to VND 55.7 bn in 2025, supporting an EPS of VND 1,547 per share and a dividend yield of 0.7%.
Diễn giải định giá
Blend of a 10-year FCF DCF (70%) and a PE multiple (30%) calibrated via isotonic mapping to observed outcomes.
- Base free cash flow (model input): VND 43,179,043,781 (base_fcf).
- WACC 10.0% and terminal growth 4.0%; terminal value accounts for 57.08% of enterprise value (tv_pct 0.5708).
- Fair PE assumed 17.12 with PE cap at 25; model fair-value per-share PE output equals VND 26,500 (pe_intrinsic).
- Projection horizon 10 years; model growth rate 4.94% driven by a ROIC of 9.3% and reinvestment rate 82.53%.
The blended intrinsic value of VND 26,866 produces only a 1.4% upside and is backed by a very_low confidence calibration. Given the narrow implied upside, concentration risks and illiquidity, conviction is weak — the valuation does not provide sufficient cushion for execution or market structure risks.
Các luận điểm cần cân nhắc
- Moderate profitability: ROE of 11.6% and EBIT margin of 10.7% imply the business can generate returns above cash alternatives.
- Profitability trend: net profit expanded from VND 31.5 bn in 2023 to VND 55.7 bn in 2025, demonstrating capacity to grow bottom-line even with modest revenue growth.
- Reasonable valuation anchors: the blended model uses a fair PE of 17.12x and a WACC of 10.0%, which are not aggressive relative to peers; upside exists if execution improves and liquidity returns.
- Minimal margin of safety: implied upside only +1.4% with very_low model confidence — limited downside protection for investors.
- Liquidity and marketability: avg daily volume 2-week is 5,087 shares and UPCom listing with 'illiquid' sanity flag increases execution risk and wide spreads.
- Ownership concentration: largest shareholder holds 41.46%, which amplifies minority shareholder governance risk and limits float (foreign_room 0.0%).
- Leverage and balance-sheet items: Debt/Equity at 0.8926 combined with reported net debt ~VND 259.3 bn increases sensitivity to demand shocks and working-capital cycles.
Bối cảnh ngành
The Vietnamese pharmaceuticals sector combines regulated distribution, hospital procurement dynamics, and manufacturing. Local accounting (VAS) can produce differences in deferred recognition versus IFRS — monitor inventory valuation and receivables closely. State banking credit quotas (SBV guidance) and the limited foreign room common in small-cap UPCom names can constrain external funding and strategic investors. Peer median upside in our coverage is ~12.1%, suggesting DHD's implied upside is below typical sector opportunity. Small-cap pharma names trade with liquidity premiums/discounts; DHD's UPCom listing and low turnover increase execution risk compared with HoSE-listed peers.
Yếu tố rủi ro
- Illiquidity: avg_volume_2w 5,087 shares and UPCom listing increase bid/ask spreads and limit ability to scale positions.
- Concentrated ownership: top shareholder owns 41.46%, reducing free float and potentially leading to governance or related-party risks.
- Narrow valuation cushion: intrinsic upside only +1.4% with very_low model confidence leaves little room for execution or macro shocks.
- Working-capital and leverage: Debt/Equity 0.8926 and net debt ~VND 259.3 bn make the company sensitive to changes in receivables/inventory cycles.
- Sector/regulatory risks: changes in procurement rules, hospital tendering, or drug price controls would directly hit revenues/margins.
- Foreign participation locked: foreign_room 0.0% prevents FDI/strategic foreign buyers from increasing liquidity or valuation support.
Yếu tố có thể tác động
- Improved trading liquidity or uplisting to HOSE could widen investor base and re-rate multiples.
- Strong quarterly earnings above current guidance that materially raise our growth assumptions and ROIC trajectory.
- Corporate actions that reduce shareholder concentration (stake sell-down) or open foreign room would be positive for liquidity and valuation.
Đánh giá dấu hiệu kế toán
No Beneish M-Score provided and there are no forensic red flags in the input. Earnings quality is 75/100, indicating reasonably solid reported earnings quality by our measures. Nevertheless, the reportable concerns are structural: high ownership concentration (41.46%), UPCom listing illiquidity, and limited transparency that often accompanies small-cap local names. Monitor related-party transactions and receivable/inventory disclosures in financial statements for signs of earnings management.
Lịch sử định giá
The model's historical track record shows a hit rate of 77.8% over 10 years and an average implied upside on past calls of +210.0%; this suggests the framework has produced positive directional calls historically. However, past performance is not a guarantee — average upside figures can be skewed by outliers and the current calibration flags very_low confidence and illiquidity for this specific stock, so rely on caution when extrapolating historical model success to DHD.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.